证券代码：920009 证券简称：丹娜生物 公告编号：2025-132 丹娜（天津）生物科技股份有限公司 第二届董事会第二十七次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 12 月 3 日 2.会议召开地点：公司第三会议室 6.会议列席人员：高级管理人员 7.召开情况合法合规的说明： 本次会议的召集、召开、议案审议程序等方面符合《公司法》等有关法律、 行政法规、部门规章、规范性文件和《公司章程》《董事会议事规则》等有关规 定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 （一）审议通过《关于制定<独立董事专门会议工作制度>的议案》 1.议案内容： 具体内容详见公司于 2025 年 12 月 4 日在北交所信息披露平台（www.bse.cn） 3.会议召开方式：现场会议+电子通讯会议 4.发出董事会会议通知的时间和方式：2025 年 12 月 1 日以书面方式发出 ...

Investment Rating - The report maintains an "Outperform" rating for the industry [5] Core Insights - The North Exchange 50 index experienced a significant decline of 12.32% in November 2025, with the index closing at 1,387.70 points [31] - The total number of listed companies on the North Exchange reached 285, with a total market capitalization of 827.155 billion and a circulating market value of 507.712 billion, reflecting a decrease of 10.2% and 11.2% respectively [11][18] - The report highlights that all sectors within the North Exchange experienced declines, with the most significant drops in household appliances, transportation, communication, automotive, and non-ferrous metals [35] Market Overview - The trading volume for November was 16.987 billion shares, with a total transaction value of 376.778 billion, marking a month-on-month increase of 9.9% in volume and 3.1% in value [18][21] - The average daily margin balance for the North Exchange in November was 7.789 billion, showing a month-on-month increase of 2.35% [22] Valuation Metrics - As of November 28, the North Exchange 50 index had a price-to-earnings ratio (PE-TTM) of 43.07, placing it at the 67.98th percentile over the past two years, while the price-to-book ratio (PB-MRQ) was 8.89, at the 75.21st percentile [24][27] - The dividend yield was reported at 0.78, corresponding to the 26.56th percentile over the same period [24] Industry Performance - The report indicates that the North Exchange's specialized and innovative index fell by 13.44% in November, with other major indices also experiencing declines, including the Sci-Tech 50 down 6.24% and the ChiNext index down 4.23% [31] - The report notes that the North Exchange's new listings included five companies: Danna Biological, Zhongcheng Consulting, Beikang Testing, Dapeng Industrial, and Nante Technology [11][3] Policy and Events - In November 2025, the Beijing Stock Exchange introduced a series of policies aimed at enhancing market vitality and solidifying institutional foundations, achieving progress in information disclosure, institutional behavior, new stock performance, and ongoing supervision [4]

Core Insights - The chairman of Dana Biotech, Zhou Zeqi, emphasizes the importance of long-term investment in core technology for sustainable development in the biopharmaceutical industry [2][3] - Dana Biotech, founded in 2014, has become a leader in early diagnosis of fungal diseases in China and is set to be the first IVD company listed on the Beijing Stock Exchange in November 2025 [2][3] Company Development - Dana Biotech was established to address the significant gap in pathogen diagnosis, particularly in fungal diseases, which have high misdiagnosis and mortality rates [3][4] - The company’s first core product, derived from the horseshoe crab's blood, allows for rapid differentiation between fungal and bacterial infections, significantly improving diagnostic speed and accuracy [4][5] Market Potential - The market for invasive fungal disease diagnostic reagents in China is projected to grow from 240 million yuan in 2018 to 3.03 billion yuan by 2030, with a compound annual growth rate of 23.5% [4][6] - Dana Biotech has developed a "5G+ Joint Detection Scheme" that includes seven core testing projects, covering various fungal diseases and has been adopted by over 1,300 hospitals [5][6] Innovation and R&D - As of October 2025, Dana Biotech has obtained 91 domestic and international patents, including 48 invention patents, and has developed a robust innovation system supported by over 30 million yuan in annual R&D investment [6][7] - The company has established a stable R&D team of over 80 members and has developed over 70 new products through a systematic approach from laboratory to clinical application [7][8] Future Directions - The funds raised from the upcoming IPO will be allocated to the construction of a new headquarters and further R&D, focusing on invasive fungal infections and AI applications in diagnostics [8][9] - AI technology is expected to enhance diagnostic efficiency and accuracy, providing multidimensional diagnostic results to assist physicians in treatment decisions [8][9] Strategic Vision - Dana Biotech aims to become a leader in the fungal diagnostics industry, leveraging core technologies to address challenges in precise diagnosis and treatment in the health sector [9]

Core Insights - The chairman of Dana Biotech, Zhou Zeqi, emphasizes the importance of long-term investment in core technology for sustainable development in the biopharmaceutical industry [1] - Dana Biotech, founded in 2014, has become a leader in early diagnosis of fungal diseases in China and is set to be the first IVD company listed on the Beijing Stock Exchange [1][2] - The company has developed a "5G+ Joint Detection Scheme" to enhance the precision of diagnosing various pathogenic infections [1][3] Company Development - Zhou Zeqi returned to China in 2008 to contribute to the biopharmaceutical sector, identifying a significant gap in the diagnosis of pathogenic microorganisms, particularly fungal diseases [1][2] - The first core product, derived from horseshoe crab blood, allows for rapid differentiation between fungal and bacterial infections, significantly reducing diagnosis time from several days to as little as 15 minutes [2][3] - The market for invasive fungal disease diagnostic reagents in China is projected to grow from 240 million yuan in 2018 to 3.03 billion yuan by 2030, with a compound annual growth rate of 23.5% [2] Product Innovation - Dana Biotech has diversified its product offerings, including antigen-antibody tests and molecular diagnostics, and has established a robust product matrix [3][4] - The company has obtained 91 domestic and international patents and 79 medical device registrations, with unique products registered in China [4][5] - Annual R&D investment exceeds 30 million yuan, accounting for over 10% of total revenue, supporting the development of six core technology platforms [4][5] Future Prospects - The company plans to use funds from its IPO for the construction of a new headquarters and further R&D, focusing on invasive fungal infections and AI applications in diagnostics [6][7] - AI technology is expected to enhance diagnostic efficiency and accuracy, providing multidimensional diagnostic results to assist physicians [6][7] - Dana Biotech aims to establish itself as a leader in the fungal diagnostics industry, aspiring to set international standards [7]

Group 1 - The core point of the article is that Dana Biological (920009) experienced a decline of 4.03% in its stock price, with a trading volume turnover rate of 20.81% and a total transaction amount of 131 million yuan on the day of reporting [1] - Institutional investors net sold 2.5005 million yuan, while the total net selling by brokerage seats amounted to 3.0872 million yuan [1] - The stock has been listed on the "Dragon and Tiger List" 12 times in the past six months, with an average price drop of 0.78% the day after being listed and an average decline of 1.96% over the following five days [2] Group 2 - The top five brokerage seats on the "Dragon and Tiger List" had a total transaction amount of 27.9967 million yuan, with buying transactions amounting to 11.2045 million yuan and selling transactions totaling 16.7922 million yuan, resulting in a net selling of 5.5877 million yuan [2] - Specific trading details show that the top buying brokerage seat was Dongfang Caifu Securities, with a buying amount of 2.5176 million yuan and a selling amount of 0.8783 million yuan [2] - The third selling seat was an institutional special seat, which bought 457,300 yuan and sold 2.9578 million yuan, resulting in a net selling of 2.5005 million yuan [2]

Core Viewpoint - On November 26, 2025, Dana Biological (stock code: 920009) was featured on the trading leaderboard of the Beijing Stock Exchange due to a turnover rate of 20.81%, with a trading volume of 1.4986 million shares and a transaction value of 131 million yuan [1]. Trading Activity Summary - The top buying seat was from Dongfang Caifu Securities Co., Ltd., Lhasa Tuanjie Road Second Securities Business Department, with a purchase amount of approximately 2.52 million yuan [2]. - The top selling seat was from Guoxin Securities Co., Ltd., Shenzhen Hongling Middle Road Securities Business Department, with a selling amount of approximately 3.96 million yuan [2]. - Other notable buying activities included: - Everbright Securities Co., Ltd., Nanjing Zhongshan Road Business Department: approximately 2.31 million yuan [2]. - Dongfang Securities Co., Ltd., Shanghai Xuhui District Yunjin Road Securities Business Department: approximately 1.79 million yuan [2]. - Other notable selling activities included: - Guojin Securities Co., Ltd., Shenzhen Branch: approximately 3.17 million yuan [2]. - CITIC Securities Co., Ltd., Beijing Dongcheng Branch: approximately 2.68 million yuan [2].

Core Insights - Danaher Biotech (920009) experienced a 0.85% increase in stock price with a turnover rate of 20.03% and a trading volume of 127 million yuan, indicating significant trading activity [2] - Institutional investors net sold 1.6021 million yuan, while total net selling from brokerage seats reached 7.168 million yuan, suggesting a bearish sentiment among institutional players [2] - The stock has appeared on the trading leaderboard 11 times in the past six months, with an average price drop of 0.45% the day after being listed and a 5-day average decline of 1.34% [2] Trading Data Summary - The top five brokerage seats accounted for a total transaction volume of 32.8122 million yuan, with buying amounting to 12.021 million yuan and selling at 20.7912 million yuan, resulting in a net selling of 8.7702 million yuan [2] - Specific trading details include: - Buy One: Guojin Securities Shenzhen Branch, buying 3.1641 million yuan and selling 1.3912 million yuan - Buy Two: Institutional Special Seat, buying 2.9046 million yuan and selling 4.5067 million yuan - Sell One: Institutional Special Seat, with the same figures as Buy Two, indicating a strong sell-off from this seat [2]

Core Insights - Dana Biological (920009) was listed on the Longhu list on November 19, 2025, due to a turnover rate of 20.57% and a trading volume of 1.4813 million shares, amounting to a transaction value of 129 million yuan [1][2]. Group 1: Trading Activity - The top buying seat was Guojin Securities Co., Ltd. Shenzhen Branch, with a purchase amount of approximately 12.58 million yuan [1][2]. - The top selling seat was Dongfang Caifu Securities Co., Ltd. Changdu Liangjiang Avenue Securities Business Department, with a selling amount of approximately 7.81 million yuan [1][2]. - The total trading volume for Dana Biological on that day was 1.4813 million shares, with a total transaction value of 129 million yuan [1][2]. Group 2: Detailed Trading Data - The second buying seat was Guoxin Securities Co., Ltd. Shenzhen Internet Branch, with a buying amount of approximately 9.28 million yuan [2]. - Other notable buying and selling activities included various securities firms, with significant amounts traded, such as 4.37 million yuan from Guoxin Securities Shenzhen Hongling Middle Road and 2.59 million yuan from Caitong Securities [2]. - The selling activities included significant amounts from Guotou Securities and Guangfa Securities, with selling amounts of approximately 6.39 million yuan and 5.70 million yuan, respectively [2].

Core Viewpoint - Danaher Biotech (920009) experienced a decline of 2.92% today, with a turnover rate of 20.57% and a trading volume of 129 million yuan, indicating significant market activity [2] Trading Activity - The stock was listed on the North Exchange's watchlist due to its turnover rate reaching 20.57%, with a net buying amount of 5.52 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction volume of 61.01 million yuan, with a buying amount of 33.26 million yuan and a selling amount of 27.74 million yuan, resulting in a net buying of 5.52 million yuan [2] - The largest buying brokerage was Guojin Securities Shenzhen Branch, with a buying amount of 12.58 million yuan, while the largest selling brokerage was Dongfang Caifu Securities Changdu Liangjiang Avenue Branch, with a selling amount of 7.81 million yuan [2] Historical Performance - Over the past six months, the stock has appeared on the watchlist 10 times, with an average price decline of 0.19% the day after being listed and an average decline of 1.36% over the following five days [2]

Group 1 - The stock of Danna Biotechnology (920009) experienced a decline of 7.29% with a turnover rate of 26.88% and a trading volume of 177 million yuan, indicating significant market activity [2] - Institutional investors net sold 7.0494 million yuan, while brokerage seats collectively net bought 2.5829 million yuan, reflecting mixed investor sentiment [2] - The stock has appeared on the trading leaderboard nine times in the past six months, with an average price increase of 0.15% the day after being listed and an average increase of 0.28% over the following five days [2] Group 2 - The top five brokerage seats accounted for a total transaction volume of 51.7833 million yuan, with buying transactions amounting to 23.6584 million yuan and selling transactions totaling 28.1249 million yuan, resulting in a net sell of 4.4665 million yuan [2] - Specific trading details show that the leading buying brokerage was Guangfa Securities with a purchase of 10.2313 million yuan, while the top selling entity was an institutional seat with a sell amount of 78.987 million yuan [2] - The trading data indicates that the stock's volatility was notable, with a price fluctuation of 10.10% during the trading day [2]